Home › Research › Prevention and risk
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US
Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Alzheimer's & Dementia, 2024
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This observational study analyzed electronic health records of about 1.09 million US patients with type 2 diabetes and found that those prescribed semaglutide (a GLP-1 diabetes/weight-loss drug) were substantially less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes medications. The authors are explicit that this is a retrospective, observational analysis that cannot establish cause and effect — and a subsequent randomized trial (EVOKE/EVOKE+, listed separately) did not confirm a clinical benefit in people who already had early Alzheimer's disease.
What this study adds
Evidence grade: Preliminary
This is a follow-up (cohort) study of 1,090,000 participants. In this observational analysis of health records, people with type 2 diabetes prescribed semaglutide were less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes drugs. Reported effect size: HR 0.33 (95% CI 0.21-0.51) vs. insulin; HR 0.59 (95% CI 0.37-0.95) vs. other GLP-1 agonists.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, W., Wang, Q. Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., et al. (2024). Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia.
Vancouver
Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia. 2024.
BibTeX
@article{wang2024-228e687c,
author = {Wang, W. and Wang, Q. Q. and Qi, X. and Gurney, M. and Perry, G. and Volkow, N. D. and Davis, P. B. and Kaelber, D. C. and Xu, R.},
title = {{Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US}},
journal = {Alzheimer's \& Dementia},
year = {2024}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- 1.09 million patients with type 2 diabetes, no prior Alzheimer's diagnosis, compared across 8 antidiabetic drug classes over 3-year follow-up
- Semaglutide associated with lower first-time Alzheimer's diagnosis risk vs. insulin (HR 0.33, 95% CI 0.21-0.51) and vs. other GLP-1 receptor agonists (HR 0.59, 95% CI 0.37-0.95)
- Authors explicitly note limitations: observational design precludes causal inference, only 3 years of follow-up, possible diagnostic misclassification, no medication-adherence data
Why it matters
In this observational analysis of health records, people with type 2 diabetes prescribed semaglutide were less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes drugs. The authors state this cannot establish cause and effect, and a later randomized trial did not confirm a clinical benefit in people who already had early Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort
- Participants1,090,000
- Effect sizeHR 0.33 (95% CI 0.21-0.51) vs. insulin; HR 0.59 (95% CI 0.37-0.95) vs. other GLP-1 agonists
- Evidence strengthPreliminary
Limitations
Observational/retrospective design precludes causal inference; only 3 years of follow-up; possible diagnostic misclassification; no medication-adherence data; a subsequent RCT (EVOKE/EVOKE+) found no benefit once Alzheimer's was already symptomatic.
How this study scored 68/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 42 of the 62 points we could judge it on, which is 68 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 2 / 5 | Rated “preliminary” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 1,090,000 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 42 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 42 of the 62 points we could judge it on is 68 out of 100. |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Prevention and risk from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.